Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical validation study of urinary clusterin and EGF in patients with chronic kidney disease
2023-507449-27-00Phase 4Withdrawn
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of finerenone, dapagliflozin and ambrisentan in chronic kidney disease (CKD) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Change in albuminuria (UACR) from baseline to week 36. Planned start Jun 2024; status: withdrawn.
02
Drugs
finerenonedapagliflozinambrisentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-507449-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507449-27-00.